Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (8): 1127-1134.doi: 10.12092/j.issn.1009-2501.2026.08.013
Yujie YANG1,2(
), Lili ZHANG1,2, Xinyun PAN1,2, Yingpeng DING3,*(
), Zhongqun WANG1,2,*(
)
Received:2025-12-14
Revised:2026-02-08
Online:2026-08-26
Published:2026-09-09
Contact:
Yingpeng DING,Zhongqun WANG
E-mail:1328044834@qq.com;doctording0556@163.com;wangtsmc@126.com
CLC Number:
Yujie YANG, Lili ZHANG, Xinyun PAN, Yingpeng DING, Zhongqun WANG. Advances in the construction and application of animal models for diabetic macrovascular complications[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(8): 1127-1134.
| 物种 | 建模策略 | 主要心血管表型 | 模型优势 | 主要局限性 | 主要转化应用 | 参考文献 |
| 非人灵 长类 | STZ ±高脂饮食;自发性糖尿病 | 进展性动脉粥样硬化;心肌梗死 | 代谢及血管特征与人类最为接近 | 成本高;伦理限制严格 | 晚期转化研究 | [ |
| 猪 | 高脂饮食 ± STZ;遗传性血脂异常模型 | 伴坏死核心及钙化的冠状动脉斑块 | 冠状动脉解剖结构与人类相似 | 诱导周期长;饲养与维护成本高 | 介入治疗及器械评价 | [ |
| 兔 | 高胆固醇饮食 ± 血管损伤 | 富脂性动脉粥样硬化斑块 | CETP 依赖的脂质代谢方式与人类相近 | 自发性冠状动脉受累有限 | 斑块生物学研究 | [ |
| 小鼠 | 遗传模型;STZ + 高脂饮食 | 动脉粥样硬化;糖尿病性心肌病 | 重复性好;遗传操作性强 | 斑块破裂少见 | 机制性研究 | [ |
| 大鼠 | 遗传或化学诱导 | 心肌损伤;轻度动脉粥样硬化 | 操作简便;代谢表型稳定 | 对动脉粥样硬化相对耐受 | 代谢–血管相互作用研究 | [ |
| 斑马鱼 | 高糖或高脂环境饲养 | 心肌病变;血管脂质沉积 | 适于高通量研究;体内实时成像 | 缺乏自发性冠状动脉血栓形成 | 药物筛选及毒性评估 | [ |
Table 1 Construction of animal models for cardiovascular complications of diabetes
| 物种 | 建模策略 | 主要心血管表型 | 模型优势 | 主要局限性 | 主要转化应用 | 参考文献 |
| 非人灵 长类 | STZ ±高脂饮食;自发性糖尿病 | 进展性动脉粥样硬化;心肌梗死 | 代谢及血管特征与人类最为接近 | 成本高;伦理限制严格 | 晚期转化研究 | [ |
| 猪 | 高脂饮食 ± STZ;遗传性血脂异常模型 | 伴坏死核心及钙化的冠状动脉斑块 | 冠状动脉解剖结构与人类相似 | 诱导周期长;饲养与维护成本高 | 介入治疗及器械评价 | [ |
| 兔 | 高胆固醇饮食 ± 血管损伤 | 富脂性动脉粥样硬化斑块 | CETP 依赖的脂质代谢方式与人类相近 | 自发性冠状动脉受累有限 | 斑块生物学研究 | [ |
| 小鼠 | 遗传模型;STZ + 高脂饮食 | 动脉粥样硬化;糖尿病性心肌病 | 重复性好;遗传操作性强 | 斑块破裂少见 | 机制性研究 | [ |
| 大鼠 | 遗传或化学诱导 | 心肌损伤;轻度动脉粥样硬化 | 操作简便;代谢表型稳定 | 对动脉粥样硬化相对耐受 | 代谢–血管相互作用研究 | [ |
| 斑马鱼 | 高糖或高脂环境饲养 | 心肌病变;血管脂质沉积 | 适于高通量研究;体内实时成像 | 缺乏自发性冠状动脉血栓形成 | 药物筛选及毒性评估 | [ |
| 模型 | 主要优势 | 主要局限性 | 典型研究用途 | 参考文献 |
| 短暂性大脑中动脉阻断模型(tMCAo) | 缺血范围明确;半暗带可重复性好;可实现再灌注 | 个体间梗死体积差异较大;技术要求高;术后并发症较多 | 超急性期缺血性脑损伤机制;溶栓及神经保护干预的评价 | [ |
| 光栓塞性脑梗死模型 | 重复性高;局灶性皮层损伤;无需开颅 | 缺乏真实半暗带;损伤局限于浅表皮层 | 微血管血栓形成机制;药物疗效的初步筛选 | [ |
| 永久性大脑中动脉阻断模型(pMCAo) | 手术操作简单、快速;围手术期死亡率低 | 缺乏再灌注成分;功能缺损较轻 | 慢性脑缺血;卒中后认知障碍及血管性痴呆研究 | [ |
| 高脂饮食/链脲佐菌素(HFD/STZ)+ tMCAo | 联合2型糖尿病代谢异常与急性缺血损伤;临床相关性高 | 诱导期较长;血糖异质性显著;需加强代谢监测 | 糖尿病加重卒中损伤机制;代谢—神经保护联合干预策略 | [ |
| db/db小鼠+ MCA阻断 | 稳定的高血糖与胰岛素抵抗状态;慢性低灌注 | 成本高;饲养条件要求高;易发生自发性微出血 | 糖尿病相关慢性脑血管损伤;代谢异常与神经退行性变相互作用 | [ |
Table 2 Construction of animal experimental models for diabetes with acute cerebrovascular disease
| 模型 | 主要优势 | 主要局限性 | 典型研究用途 | 参考文献 |
| 短暂性大脑中动脉阻断模型(tMCAo) | 缺血范围明确;半暗带可重复性好;可实现再灌注 | 个体间梗死体积差异较大;技术要求高;术后并发症较多 | 超急性期缺血性脑损伤机制;溶栓及神经保护干预的评价 | [ |
| 光栓塞性脑梗死模型 | 重复性高;局灶性皮层损伤;无需开颅 | 缺乏真实半暗带;损伤局限于浅表皮层 | 微血管血栓形成机制;药物疗效的初步筛选 | [ |
| 永久性大脑中动脉阻断模型(pMCAo) | 手术操作简单、快速;围手术期死亡率低 | 缺乏再灌注成分;功能缺损较轻 | 慢性脑缺血;卒中后认知障碍及血管性痴呆研究 | [ |
| 高脂饮食/链脲佐菌素(HFD/STZ)+ tMCAo | 联合2型糖尿病代谢异常与急性缺血损伤;临床相关性高 | 诱导期较长;血糖异质性显著;需加强代谢监测 | 糖尿病加重卒中损伤机制;代谢—神经保护联合干预策略 | [ |
| db/db小鼠+ MCA阻断 | 稳定的高血糖与胰岛素抵抗状态;慢性低灌注 | 成本高;饲养条件要求高;易发生自发性微出血 | 糖尿病相关慢性脑血管损伤;代谢异常与神经退行性变相互作用 | [ |
| 研究目的 | 优选模型 | 主要优势 | 主要局限性 | 推荐主要终点指标 | 参考文献 |
| 分子机制研究(血管生成、氧化应 激等) | db/db 小鼠 + 股动脉结扎(FAL) | 高血糖状态稳定;遗传背景一致;转基因与基因修饰工具成熟 | 缺乏明确动脉粥样硬化病变;年轻小鼠再灌注恢复较快 | 缺血侧/对侧足部 灌注比值(激光多 普勒) | [ |
| 动脉粥样硬化驱动的 PAD | STZ 处理的 C57BL/6 小鼠 + FAL | 内皮功能障碍与斑块性狭窄并存;脂质代谢特征更接近人类 T2DM-PAD | 需联合高脂饮食;建模周期较长、成本较高 | 斑块负荷–灌注复合评分 | [ |
| 影像学评估及干预手段验证 | 四氧嘧啶(alloxan) + 高胆固醇饮食 + FAL(兔) | 血管口径较大;影像学评估流程(CT/DSA/超声)与临床高度一致 | 需长期高胆固醇喂养;阿洛糖具有一定肾毒性 | 第21天 CT 评估 Rutherford 分级 ≥3 | [ |
| 腔内介入器械评价 | STZ + 球囊损伤(猪) | 动脉直径接近人类;适用于导管及介入器械操作 | 成本高;实验室应用与验证相对有限 | 血管造影通畅率及再狭窄程度 | [ |
Table 3 Experimental models for diabetes with peripheral arterial disease for different research purposes
| 研究目的 | 优选模型 | 主要优势 | 主要局限性 | 推荐主要终点指标 | 参考文献 |
| 分子机制研究(血管生成、氧化应 激等) | db/db 小鼠 + 股动脉结扎(FAL) | 高血糖状态稳定;遗传背景一致;转基因与基因修饰工具成熟 | 缺乏明确动脉粥样硬化病变;年轻小鼠再灌注恢复较快 | 缺血侧/对侧足部 灌注比值(激光多 普勒) | [ |
| 动脉粥样硬化驱动的 PAD | STZ 处理的 C57BL/6 小鼠 + FAL | 内皮功能障碍与斑块性狭窄并存;脂质代谢特征更接近人类 T2DM-PAD | 需联合高脂饮食;建模周期较长、成本较高 | 斑块负荷–灌注复合评分 | [ |
| 影像学评估及干预手段验证 | 四氧嘧啶(alloxan) + 高胆固醇饮食 + FAL(兔) | 血管口径较大;影像学评估流程(CT/DSA/超声)与临床高度一致 | 需长期高胆固醇喂养;阿洛糖具有一定肾毒性 | 第21天 CT 评估 Rutherford 分级 ≥3 | [ |
| 腔内介入器械评价 | STZ + 球囊损伤(猪) | 动脉直径接近人类;适用于导管及介入器械操作 | 成本高;实验室应用与验证相对有限 | 血管造影通畅率及再狭窄程度 | [ |
| 1 |
GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2023, 402 (10397): 203- 234.
doi: 10.1016/S0140-6736(23)01301-6 |
| 2 |
Yu MG, Gordin D, Fu J, et al. Protective factors and the pathogenesis of complications in diabetes[J]. Endocr Rev, 2024, 45 (2): 227- 252.
doi: 10.1210/endrev/bnad030 |
| 3 |
Hamrangsekachaee M, Wen K, Bencherif SA, et al. Atherosclerosis and endothelial mechanotransduction: current knowledge and models for future research[J]. Am J Physiol Cell Physiol, 2023, 324 (2): C488- C504.
doi: 10.1152/ajpcell.00449.2022 |
| 4 |
Khan AW, Jandeleit-Dahm KAM. Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches[J]. Nat Rev Cardiol, 2025, 22 (7): 482- 496.
doi: 10.1038/s41569-024-01115-w |
| 5 |
Litwak KN, Cefalu WT, Wagner JD. Chronic hyperglycemia increases arterial low-density lipoprotein metabolism and atherosclerosis in cynomolgus monkeys[J]. Metabolism, 1998, 47 (8): 947- 954.
doi: 10.1016/S0026-0495(98)90349-3 |
| 6 |
Lv Y, Li K, Wang S, et al. Protective role of arachidonic acid against diabetic myocardial ischemic injury: a translational study of pigs, rats, and humans[J]. Cardiovasc Diabetol, 2024, 23, 58.
doi: 10.1186/s12933-024-02123-3 |
| 7 |
Tan MY, Xia B, Xiao Z, et al. Development of a new model for acute myocardial infarction in rabbits[J]. J Vet Med Sci, 2017, 79 (3): 467- 473.
doi: 10.1292/jvms.16-0114 |
| 8 |
Xie SY, Liu SQ, Zhang T, et al. USP28 serves as a key suppressor of mitochondrial morphofunctional defects and cardiac dysfunction in the diabetic heart[J]. Circulation, 2024, 149 (9): 684- 706.
doi: 10.1161/CIRCULATIONAHA.123.065603 |
| 9 |
Zhao Y, Li W, Zhang D. Gycyrrhizic acid alleviates atherosclerotic lesions in rats with diabetes mellitus[J]. Mol Med Rep, 2021, 24 (5): 755.
doi: 10.3892/mmr.2021.12395 |
| 10 |
Chablais F, Jaźwińska A. Induction of myocardial infarction in adult zebrafish using cryoinjury[J]. J Vis Exp, 2012 (62): e3666.
doi: 10.3791/3666 |
| 11 |
Charlot A, Bringolf A, Mallard J, et al. Hypercaloric low-carbohydrate high-fat diet protects against the development of nonalcoholic fatty liver disease in obese mice in contrast to isocaloric Western diet[J]. Front Nutr, 2024, 11, 1366883.
doi: 10.3389/fnut.2024.1366883 |
| 12 |
Cooper MA, O’Meara B, Jack MM, et al. Intrinsic activity of C57BL/6 substrains associates with high-fat diet-induced mechanical sensitivity in mice[J]. J Pain, 2018, 19 (11): 1285- 1295.
doi: 10.1016/j.jpain.2018.05.005 |
| 13 | Jin Y, Kozan D, Anderson JL, et al. A high-cholesterol zebrafish diet promotes hypercholesterolemia and fasting-associated liver triglycerides accumulation [J]. bioRxiv, 2023: 2023.11. 01.565134. |
| 14 |
Ebert MLA, Schmidt VF, Öcal O, et al. A minimally invasive animal model of atherosclerosis and neointimal hyperplasia for translational research[J]. Eur Radiol Exp, 2025, 9 (1): 14.
doi: 10.1186/s41747-025-00558-1 |
| 15 | Li M, Delafontaine P, Sukhanov S. Coronary atherosclerotic plaque composition and classification in hypercholesterimic pigs [J]. bioRxiv, 2025: 2025.06. 06.658319. |
| 16 |
Jia L, Qu P, Zhao Y, et al. Tripeptide DT-109 (gly-gly-leu) attenuates atherosclerosis and vascular calcification in nonhuman primates[J]. Signal Transduct Target Ther, 2025, 10 (1): 122.
doi: 10.1038/s41392-025-02201-2 |
| 17 | Xiong L, Diwakarla S, Chatzis R, et al. Acute exposure to high-fat diet impairs ILC3 functions and gut homeostasis [J]. Immunity, 2025, 58(5): 1185-1200. e8. |
| 18 |
Zhang Z, Xu Y, Pang K, et al. Microbiota humanization drives human-like metabolic and immune transcriptomic shifts in pigs[J]. iMetaOmics, 2025, 2 (3): e70034.
doi: 10.1002/imo2.70034 |
| 19 |
Nan G, Wang B, Lv X, et al. Effects of rhaponticum carthamoides (willd. ) iljin on endothelial dysfunction and the inflammatory response in type 2 diabetes mellitus mice[J]. Phytomedicine, 2024, 135, 156134.
doi: 10.1016/j.phymed.2024.156134 |
| 20 | Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas[J]. Physiol Res, 2001, 50 (6): 537- 546. |
| 21 |
Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes[J]. Diabetologia, 2008, 51 (2): 216- 226.
doi: 10.1007/s00125-007-0886-7 |
| 22 |
Akinlade OM, Owoyele BV, Soladoye AO. Streptozotocin-induced type 1 and 2 diabetes in rodents: a model for studying diabetic cardiac autonomic neuropathy[J]. Afr Health Sci, 2021, 21 (2): 719- 727.
doi: 10.4314/ahs.v21i2.30 |
| 23 |
Liu C, Wu K, Gao H, et al. Current strategies and potential prospects for nanoparticle-mediated treatment of diabetic nephropathy[J]. Diabetes Metab Syndr Obes, 2022, 15, 2653- 2673.
doi: 10.2147/DMSO.S380550 |
| 24 |
Zhou L, Yao S. Recent advances in therapeutic CRISPR-Cas9 genome editing: mechanisms and applications[J]. Mol Biomed, 2023, 4 (1): 10.
doi: 10.1186/s43556-023-00115-5 |
| 25 |
Ge X, Wang S, Li Z, et al. Lactate-activated GPR132-src signal induces macrophage senescence and aggravates atherosclerosis under diabetes[J]. Adv Sci (Weinh), 2025, 12 (33): e00141.
doi: 10.1002/advs.202500141 |
| 26 |
Shamsuzzaman S, Deaton RA, Salamon A, et al. Novel mouse model of myocardial infarction, plaque rupture, and stroke shows improved survival with myeloperoxidase inhibition[J]. Circulation, 2024, 150 (9): 687- 705.
doi: 10.1161/CIRCULATIONAHA.123.067931 |
| 27 |
Wu LD, Shi Y, Kong CH, et al. The GRK2/AP-1 signaling axis mediates vascular endothelial dysfunction and atherosclerosis induced by oscillatory low shear stress[J]. Adv Sci (Weinh), 2025, 12 (33): e01981.
doi: 10.1002/advs.202501981 |
| 28 |
Yun Y, Zhang C, Guo S, et al. Identification of betulinic acid derivatives as potent TGR5 agonists with antidiabetic effects via humanized TGR5H88Y mutant mice[J]. J Med Chem, 2021, 64 (16): 12181- 12199.
doi: 10.1021/acs.jmedchem.1c00851 |
| 29 | Bae H, Jung S, Le J, et al. Cross-organ metabolite production and consumption in healthy and atherogenic conditions [J]. Cell, 2025, 188(16): 4441-4455. e16. |
| 30 |
Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates[J]. Nature, 2021, 593 (7859): 429- 434.
doi: 10.1038/s41586-021-03534-y |
| 31 |
Jin H, Zhang C, Nagenborg J, et al. Genome-scale metabolic network of human carotid plaque reveals the pivotal role of glutamine/glutamate metabolism in macrophage modulating plaque inflammation and vulnerability[J]. Cardiovasc Diabetol, 2024, 23 (1): 240.
doi: 10.1186/s12933-024-02339-3 |
| 32 |
Goutchtat R, Quenon A, Clarisse M, et al. Effects of subtotal pancreatectomy and long-term glucose and lipid overload on insulin secretion and glucose homeostasis in minipigs[J]. Endocrinol Diabetes Metab, 2023, 6 (4): e425.
doi: 10.1002/edm2.425 |
| 33 |
Zhang WX, Tai GJ, Li XX, et al. Inhibition of neointima hyperplasia by the combined therapy of linagliptin and metformin via AMPK/Nox4 signaling in diabetic rats[J]. Free Radic Biol Med, 2019, 143, 153- 163.
doi: 10.1016/j.freeradbiomed.2019.07.030 |
| 34 |
Kashyap S, Engel S, Osman M, et al. Cardiovascular manifestations of renovascular hypertension in diabetic mice[J]. PeerJ, 2016, 4, e1736.
doi: 10.7717/peerj.1736 |
| 35 |
Bao XL, Dai Y, Lu L, et al. Vasostatin-2 associates with coronary collateral vessel formation in diabetic patients and promotes angiogenesis via angiotensin-converting enzyme 2[J]. Eur Heart J, 2023, 44 (19): 1732- 1744.
doi: 10.1093/eurheartj/ehad082 |
| 36 |
Jia Y, Zhao Y, Niu M, et al. Preliminary study of metabonomic changes during the progression of atherosclerosis in miniature pigs[J]. Animal Model Exp Med, 2024, 7 (4): 419- 432.
doi: 10.1002/ame2.12462 |
| 37 |
Leaver HA, Craig SR, Yap PL, et al. Lymphocyte responses following open and minimally invasive thoracic surgery[J]. Eur J Clin Invest, 2000, 30 (3): 230- 238.
doi: 10.1046/j.1365-2362.2000.00622.x |
| 38 | Rostami N, Gomari MM, Choupani E, et al. Exploring advanced CRISPR delivery technologies for therapeutic genome editing[J]. Small Sci, 2024, 4 (10): 2400192. |
| 39 |
Ma H, Xu J, Fang H, et al. A capsule-based scaffold incorporating decellularized extracellular matrix and curcumin for islet beta cell therapy in type 1 diabetes mellitus[J]. Biofabrication, 2024, 16 (4): 045038.
doi: 10.1088/1758-5090/ad7907 |
| 40 |
Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications[J]. Nat Rev Nephrol, 2020, 16 (7): 377- 390.
doi: 10.1038/s41581-020-0278-5 |
| 41 |
Kalaria RN, Akinyemi R, Ihara M. Stroke injury, cognitive impairment and vascular dementia[J]. Biochim Biophys Acta Mol Basis Dis, 2016, 1862 (5): 915- 925.
doi: 10.1016/j.bbadis.2016.01.015 |
| 42 |
Li W, Qu Z, Prakash R, et al. Comparative analysis of the neurovascular injury and functional outcomes in experimental stroke models in diabetic goto-kakizaki rats[J]. Brain Res, 2013, 1541, 106- 114.
doi: 10.1016/j.brainres.2013.10.021 |
| 43 |
Ngwa C, Al Mamun A, Qi S, et al. Central IRF4/5 signaling are critical for microglial activation and impact on stroke outcomes[J]. Transl Stroke Res, 2024, 15 (4): 831- 843.
doi: 10.1007/s12975-023-01172-2 |
| 44 |
Patel RB, Dhanesha N, Sutariya B, et al. Targeting neutrophil α9 improves functional outcomes after stroke in mice with obesity-induced hyperglycemia[J]. Stroke, 2023, 54 (9): 2409- 2419.
doi: 10.1161/STROKEAHA.123.042714 |
| 45 |
Ganbaatar B, Fukuda D, Shinohara M, et al. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice[J]. Eur J Pharmacol, 2020, 875, 173040.
doi: 10.1016/j.ejphar.2020.173040 |
| 46 | Yaksh TL, Woller SA, Ramachandran R, et al. The search for novel analgesics: targets and mechanisms [J]. F1000Prime Rep, 2015, 7: 56. |
| 47 | Kothari R, abdulrahim MW, oh HJ, et al. a mast cell receptor mediates post-stroke brain inflammation via a dural-brain axis [J]. Cell, 2025, 188(20): 5499-5515. e20. |
| 48 |
Bai YY, Gao X, Wang YC, et al. Image-guided pro-angiogenic therapy in diabetic stroke mouse models using a multi-modal nanoprobe[J]. Theranostics, 2014, 4 (8): 787- 797.
doi: 10.7150/thno.9525 |
| 49 |
Kastrup A, Engelhorn T, Beaulieu C, et al. Dynamics of cerebral injury, perfusion, and blood-brain barrier changes after temporary and permanent middle cerebral artery occlusion in the rat[J]. J Neurol Sci, 1999, 166 (2): 91- 99.
doi: 10.1016/S0022-510X(99)00121-5 |
| 50 |
Augestad IL, Dekens D, Karampatsi D, et al. Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice[J]. Br J Pharmacol, 2022, 179 (4): 677- 694.
doi: 10.1111/bph.15524 |
| 51 |
Zhu W, Davis CM, Allen EM, et al. Sex difference in capillary reperfusion after transient middle cerebral artery occlusion in diabetic mice[J]. Stroke, 2023, 54 (2): 364- 373.
doi: 10.1161/STROKEAHA.122.040972 |
| 52 |
Zhang SX, Yao YH, Zhang S, et al. Comparative study of DSC-PWI and 3D-ASL in ischemic stroke patients[J]. J Huazhong Univ Sci Technolog Med Sci, 2015, 35 (6): 923- 927.
doi: 10.1007/s11596-015-1529-8 |
| 53 |
Ma W, Wang C, Xiao J. A testlet diagnostic classification model with attribute hierarchies[J]. Appl Psychol Meas, 2023, 47 (3): 183- 199.
doi: 10.1177/01466216231165315 |
| 54 |
Nutma E, Fancy N, Weinert M, et al. Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases[J]. Nat Commun, 2023, 14 (1): 5247.
doi: 10.1038/s41467-023-40937-z |
| 55 |
Sharma S, Cheema M, Reeson PL, et al. A pathogenic role for IL-10 signalling in capillary stalling and cognitive impairment in type 1 diabetes[J]. Nat Metab, 2024, 6 (11): 2082- 2099.
doi: 10.1038/s42255-024-01159-9 |
| 56 |
Li Y, Liu Y, Liu S, et al. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies[J]. Signal Transduct Target Ther, 2023, 8 (1): 152.
doi: 10.1038/s41392-023-01400-z |
| 57 |
Lejay A, Wu WW, Kuntz SH, et al. What is the best experimental model for developing novel therapeutics in peripheral artery disease?[J]. Arterioscler Thromb Vasc Biol, 2024, 44 (11): 2264- 2270.
doi: 10.1161/ATVBAHA.124.321163 |
| 58 |
Yang Y, Xu Q, Li T, et al. Trimetazidine ameliorates hindlimb ischaemic damage in type 2 diabetic mice[J]. Ann Med, 2021, 53 (1): 1099- 1107.
doi: 10.1080/07853890.2021.1925147 |
| 59 |
Asadi-Yousefabad SL, Nammian P, Tabei SMB, et al. Angiogenesis in diabetic mouse model with critical limb ischemia; cell and gene therapy[J]. Microvasc Res, 2022, 141, 104339.
doi: 10.1016/j.mvr.2022.104339 |
| 60 |
Niu M, Liu Y, Xiang L, et al. Long-term case study of a wuzhishan miniature pig with diabetes[J]. Animal Model Exp Med, 2020, 3 (1): 22- 31.
doi: 10.1002/ame2.12098 |
| 61 |
Cheng HS, Pérez-Cremades D, Zhuang R, et al. Impaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b/INHBA signaling axis[J]. JCI Insight, 2023, 8 (10): e163041.
doi: 10.1172/jci.insight.163041 |
| 62 |
Yan X, Zhang H, Fan Q, et al. Dectin-2 deficiency modulates Th1 differentiation and improves wound healing after myocardial infarction[J]. Circ Res, 2017, 120 (7): 1116- 1129.
doi: 10.1161/CIRCRESAHA.116.310260 |
| 63 |
Emini Veseli B, Perrotta P, De Meyer GRA, et al. Animal models of atherosclerosis[J]. Eur J Pharmacol, 2017, 816, 3- 13.
doi: 10.1016/j.ejphar.2017.05.010 |
| 64 |
Lin JB, Phillips EH, Riggins TE, et al. Imaging of small animal peripheral artery disease models: recent advancements and translational potential[J]. Int J Mol Sci, 2015, 16 (5): 11131- 11177.
doi: 10.3390/ijms160511131 |
| 65 |
Krishna S, Moxon J, Kraeuter AK, et al. Effect of metformin in a novel experimental model of peripheral artery disease[J]. Clin Sci (Lond), 2025, 139 (15): 847- 856.
doi: 10.1042/CS20243343 |
| 66 |
Singh MV, Dokun AO. Diabetes mellitus in peripheral artery disease: beyond a risk factor[J]. Front Cardiovasc Med, 2023, 10, 1148040.
doi: 10.3389/fcvm.2023.1148040 |
| 67 |
Wang Y, Wu H, Pan Y, et al. Innovations in hydrogel therapies for diabetic wound healing: bridging the gap between pathophysiology and clinical application[J]. Burns Trauma, 2025, 13, tkaf025.
doi: 10.1093/burnst/tkaf025 |
| 68 |
Couturier A, Calissi C, Cracowski JL, et al. Mouse models of diabetes-related ulcers: a systematic review and network meta-analysis[J]. EBioMedicine, 2023, 98, 104856.
doi: 10.1016/j.ebiom.2023.104856 |
| [1] | Xuewu LIU, Dejian JIANG, Yanhua DU. Progress in pathogenesis and drug development of diabetic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 735-751. |
| [2] | Guangwei QI, Wanyu TONG, Jilu WANG, Jingwen GUO, Ruiqiao LI, Qilong WANG. Protective effects of Xueshuantong on mitochondrial dynamic balance, endothelial dysfunction, and atherosclerosis in diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 798-807. |
| [3] | Qing ZHANG, Panwei HU, Hua ZHOU. Animal model of intrauterine adhesions and its application in the treatment of intrauterine adhesions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 257-264. |
| [4] | Yayan SHI, Yu WANG, Wei KUANG, Shouyang YU. The latest progress in the pathogenesis of multiple sclerosis and drug therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(1): 78-87. |
| [5] | JING Jiawen, MENG Qingbo, BI Zheng, WANG Fanjing, LI Yufan, FANG Zhaohui. Advances in animal models of diabetic erectile dysfunction based on therapeutic approaches [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(9): 1224-1232. |
| [6] | MA Xingyu1, 2, XIE Xuejiao2, LI Chunqiao1, ZHANG Zheng1. Study on the mechanism of Xiongshi Shiwei Wendan decoction promoting RCT and treat AS based on network pharmacology, molecular docking and in vitro experiment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(8): 1026-1036. |
| [7] | LIU Dan, MIAO Jiawei, TAN Zihao, HE Chunyao, ZHAO Mingzhu, HE Xiuzhen. Progress in the pharmacological effects of naringin on cardiovascular diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 272-281. |
| [8] | XU Linlin, ZHANG Dou, DING Pengtao, XI Xiaoxia, YANG Pengfei, ZHANG Xiaoya, LI Tingbao. Protective mechanism of Guomin decoction against atopic dermatitis in mice based on TLR4/MyD88/NF-κB signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(12): 1648-1657. |
| [9] | BAI Xuechun, CHEN Shuo, LI Shanshan, LI Qinglin. Intervention study on the progress of subacute Parkinson's disease in mice with Kangzhen Zhijing spasmodic decoction Ⅰ [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 629-636. |
| [10] | ZHAO Zishuo, ZHU Yuguang, MA Yanshan, LI Zhiwei, JING Yongshuai, XIE Yinghua. Effects of different formulations of high-fat diet on establishment of a non-alcoholic fatty liver model in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(5): 543-553. |
| [11] | ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge. Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840. |
| [12] | LI Junmin, NIU Hengli, XIE Mingquan, SU Jinlong. Effects of hawthorn flavonoids on atherosclerotic and hyperlipidemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 276-282. |
| [13] | GUAN Li, CHEN Wu, SUN Junfang, LI Wei. Xintahua water extract improves the disease indexes of atherosclerosis model rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 18-23. |
| [14] | LI Mengying, SI Mingdong, WEN Zishuai, SHI Huan, LI Xinrui, ZHANG Yuanyuan, WANG Hongfang, MA Donglai, CHU Li. Mechanism of saffron in treating atherosclerosis based on network pharmacology method [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 649-657. |
| [15] | XIE Xiangmei, HUANG Zhihong, LIU Xiaoju, XUE Bing, LAN Baozhu. Effects of atorvastatin and folic acid tablets on homocysteine and carotid atherosclerosis in patients with type H hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 455-459. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||